Dexmedetomidine is neuroprotective in an in vitro model for traumatic brain injury

111Citations
Citations of this article
96Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The α 2-adrenoreceptor agonist dexmedetomidine is known to provide neuroprotection under ischemic conditions. In this study we investigated whether dexmedetomidine has a protective effect in an in vitro model for traumatic brain injury.Methods: Organotypic hippocampal slice cultures were subjected to a focal mechanical trauma and then exposed to varying concentrations of dexmedetomidine. After 72 h cell injury was assessed using propidium iodide. In addition, the effects of delayed dexmedetomidine application, of hypothermia and canonical signalling pathway inhibitors were examined.Results: Dexmedetomidine showed a protective effect on traumatically injured hippocampal cells with a maximum effect at a dosage of 1 μM. This effect was partially reversed by the simultaneous administration of the ERK inhibitor PD98059.Conclusion: In this TBI model dexmedetomidine had a significant neuroprotective effect. Our results indicate that activation of ERK might be involved in mediating this effect. © 2012 Schoeler et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Schoeler, M., Loetscher, P. D., Rossaint, R., Fahlenkamp, A. V., Eberhardt, G., Rex, S., … Coburn, M. (2012). Dexmedetomidine is neuroprotective in an in vitro model for traumatic brain injury. BMC Neurology, 12. https://doi.org/10.1186/1471-2377-12-20

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free